Liver organoids are miniature, three-dimensional tissue structures grown from stem cells or primary liver cells that self-organize to mimic much of the architecture and function of a real human liver. They emerged over the past decade as researchers recognized that flat cell cultures and animal models were failing to predict how human livers actually respond to drugs, disease, and injury. Today, liver organoids sit at the center of several fields: they model diseases from hepatitis B to liver cancer, they screen drugs for toxicity with sensitivity and specificity figures approaching 89%, and early animal studies suggest they could one day be transplanted to rescue failing livers.
How Liver Organoids Are Built
The starting material for a liver organoid is usually one of two cell types: adult stem cells harvested from liver tissue, or induced pluripotent stem cells (iPSCs) reprogrammed from a patient’s own blood or skin cells. Both can be coaxed, through carefully timed cocktails of growth factors, into forming tiny spheres of liver-like tissue that contain hepatocytes (the main working cells of the liver), cholangiocytes (bile duct cells), and sometimes additional support cells. These spheres grow in a gel matrix that provides physical scaffolding, traditionally a protein mixture called Matrigel derived from mouse tumor cells.
The reliance on Matrigel has been a sore point. Its composition varies from batch to batch, it comes from animals, and that makes regulatory approval for clinical applications harder. Researchers have developed synthetic alternatives using polyethylene glycol (PEG) hydrogels tuned to match the stiffness of actual liver tissue, roughly 1.3 kilopascals. Adding just a minimal adhesive peptide sequence to the otherwise inert gel was enough to let liver progenitor cells proliferate as efficiently as they do in Matrigel.1Nature Communications. Mechano-modulatory synthetic niches for liver organoid derivation That finding matters because it opens a path toward fully defined, animal-free culture systems suitable for clinical-grade production.
Adding Complexity With Multiple Cell Types
A real liver is not just hepatocytes. It contains stellate cells that store vitamin A and drive scarring when activated, endothelial cells lining blood vessels, immune cells like Kupffer macrophages, and bile duct cells. Early organoids captured only a fraction of this diversity, but newer protocols deliberately assemble multiple cell types together. One approach differentiates iPSCs separately into hepatoblasts, stellate cells, endothelial cells, and macrophages, then combines them in U-bottom plates and lets them self-organize into spheroids over about three weeks.2Biofabrication. Human iPSC-derived liver co-culture spheroids to model liver fibrosis Another uses HepaRG cells (a well-characterized hepatocyte line), primary human macrophages, and stellate-cell-derived LX-2 cells to build what the researchers call multi-cell-type liver organoids.3PubMed. 3D multi-cell-type liver organoids: A new model of non-alcoholic fatty liver disease for drug safety assessments
One of the more detailed multi-cell-type systems uses human pluripotent stem cells to produce organoids containing not just hepatocytes but also a putative stellate cell population. Single-cell RNA sequencing identified both activated and quiescent stellate cell states within the organoids, and imaging revealed star-shaped cells with long branching processes characteristic of stellate cells in a living liver.4Experimental & Molecular Medicine. Scalable production of tissue-like vascularized liver organoids from human PSCs Including stellate cells is particularly important for modeling fibrosis, the scarring process behind cirrhosis, because stellate cell activation is the central event driving that disease.
Recreating Bile Flow and Hepatobiliary Connections
One function that distinguishes the liver from most other organs is bile production and transport. Hepatocytes make bile, secrete it into tiny channels called bile canaliculi, and those channels drain into bile ducts lined by cholangiocytes. Replicating that plumbing in a dish has been a significant engineering challenge, but several groups have now demonstrated hepatobiliary organoids where bile analogs move through the system the way they do in a body.
In one study, hepatocytes within organoids absorbed fluorescent bile acid, secreted it into bile canaliculi, and the labeled compound accumulated in the biliary structures over a six-hour period. The organoids also took up bilirubin, metabolized it, and transported it through the same canalicular-to-biliary route.5Nature Communications. Generation of functional liver organoids on combining hepatocytes and cholangiocytes with hepatobiliary connections ex vivo Other teams have independently confirmed this bile-transport capacity using different cell sources, including chemically induced liver progenitor cells and iPSC-derived systems.6PubMed Central. Generation of human hepatobiliary organoids with a functional bile duct from chemically induced liver progenitor cells 7PubMed. Establishment of human induced pluripotent stem cell-derived hepatobiliary organoid with bile duct for pharmaceutical research use These hepatobiliary organoids are particularly useful for studying cholestatic liver diseases, where bile flow is impaired, and for testing whether drugs might cause bile-related toxicity.
Organ-on-Chip Platforms and Fluid Flow
Growing organoids in static gel is one thing. Placing them inside a microfluidic chip where nutrient-rich media flows past them, mimicking blood circulation, is another. These “organ-on-chip” or “liver-on-chip” systems add a layer of physiological realism that static culture cannot provide. When liver organoids were cultured alongside endothelial cells under fluid shear, key drug-metabolizing enzymes like CYP3A4 and CYP2C9 were expressed at higher levels than in static conditions, while bile duct markers were modestly suppressed, suggesting the flow pushed the cells toward a more mature hepatocyte identity.8PubMed Central. A human liver organoids-on-chip for the assessment of drug-induced liver injury
High-throughput chip designs have also emerged. One platform uses 16-well chips compatible with standard laboratory plate readers and liquid-handling robots, enabling automated drug-screening workflows that would be impractical with traditional organoid culture.9Cellular and Molecular Gastroenterology and Hepatology. A High-Throughput Microphysiological Liver Chip System to Model Drug-Induced Liver Injury Using Human Liver Organoids The aim is to bring organoid testing up to the speed pharmaceutical companies need, where thousands of compounds must be screened in parallel.
Modeling Liver Diseases
Liver organoids have become go-to tools for recreating diseases that are otherwise difficult to study outside the body. The applications span metabolic, infectious, and malignant diseases.
Fatty Liver Disease
Metabolic dysfunction-associated steatotic liver disease (formerly called non-alcoholic fatty liver disease) affects roughly a quarter of the world’s population, yet researchers have struggled to model its full progression in cell culture. Organoid models now show progressive decline in hepatocyte viability alongside increasing lipid accumulation, mirroring what happens in patients as the disease worsens.10PubMed Central. Three-Dimensional Dynamic Cell Models for Metabolic Dysfunction-Associated Steatotic Liver Disease Progression More advanced versions recapitulate the hallmark features of metabolic-associated steatohepatitis (MASH), including disrupted glucose and lipid metabolism and inflammatory immune dysregulation, and have been used to test potential therapies such as plant-derived polysaccharides.11Food Bioscience. Construction and application of a MASH-like liver organoid model reveals the metabolic modulatory effects of Angelica sinensis polysaccharide iPSC-derived organoids have also been used to verify the lipid-lowering effects of semaglutide, the active ingredient in certain GLP-1 receptor agonist drugs now widely prescribed for diabetes and obesity.12Cell Proliferation / Wiley Online Library. Liver Organoids: From Disease Modelling to Regenerative Medicine
Hepatitis B
Hepatitis B virus (HBV) has been notoriously hard to study in culture because the virus is exquisitely picky about its host cells. Primary human hepatocytes lose their ability to support infection quickly after being isolated. Liver organoids overcome this limitation. Once differentiated to a hepatocyte-like state, tissue-derived organoids support the full HBV replication cycle when coupled with an adenoviral delivery system.13PubMed. A Robust Human Liver Organoid Model of Hepatitis B Virus Infection iPSC-derived hepatic organoids go a step further: they stably express the receptor HBV uses to enter cells, remain viable under infection conditions for at least 20 days, and sustain secretion of viral antigens throughout.14BioScience Trends. Modeling of the hepatitis B virus life cycle and the efficacy of antivirals in human iPSC-derived hepatic organoids These models let researchers test antiviral drugs against every stage of the viral life cycle, something that was extremely difficult before.
Liver Cancer
Patient-derived tumor organoids are reshaping how researchers think about precision cancer therapy. A large biobank of 399 tumor organoids derived from 144 liver cancer patients captured both the genomic landscape and the histological appearance of the original tumors and proved reliable for drug sensitivity screening, with results validated against patient responses and animal models.15Cancer Cell. A living biobank of liver cancer organoids unveils inter- and intra-tumor heterogeneity for precision medicine A complementary biobank used multi-omics profiling, including genomic, epigenomic, transcriptomic, and proteomic analysis, to characterize organoids representing various liver cancer subtypes.16PubMed Central. Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology The practical value is straightforward: you can grow a patient’s tumor in miniature, test a panel of drugs against it, and identify the treatment most likely to work before the patient ever receives it.
Drug Toxicity Screening
Drug-induced liver injury is one of the leading reasons drugs fail in clinical trials or get pulled from the market after approval. Traditional cell lines and animal models miss too many signals because they lack human-specific metabolic pathways or because their drug-processing enzymes behave differently from ours. This is where liver organoids offer a genuine advantage. A high-throughput screen using iPSC-derived liver organoids tested 238 marketed drugs at four concentrations and achieved roughly 89% sensitivity and 89% specificity in predicting liver toxicity.17PubMed Central. High-Fidelity Drug-Induced Liver Injury Screen Using Human Pluripotent Stem Cell-Derived Organoids That performance is a substantial improvement over traditional preclinical models.
The drug-metabolizing enzyme profile of organoids matters enormously for these screens. Some enzymes match primary human hepatocyte levels well. CYP3A4, which metabolizes roughly half of all prescription drugs, shows comparable activity in organoids and in freshly isolated hepatocytes. But other enzymes like CYP2B6 and CYP2D6 still lag behind.18PubMed Central. Drug Metabolism of Hepatocyte-like Organoids and Their Applicability in In Vitro Toxicity Testing Researchers have shown that enzyme activity can be boosted by treating organoids with known inducers and that the induced organoids metabolize drugs more rapidly, confirming they can recapitulate inducible drug metabolism.19PubMed. Development of organoid-based drug metabolism model
Microphysiological systems that incorporate liver organoids alongside cells from other species can also tease apart species-specific toxicity differences. A comparative study using human, monkey, rat, and dog hepatocytes in a perfusion-based platform showed that species-specific drug effects, for compounds like bosentan and fialuridine that are toxic in some species but not others, were reflected in the system’s readouts.20PubMed Central. Comparative Analysis of Species-Specific Hepatocyte Function and Drug Effects in a Liver Microphysiological System PhysioMimix LC12 and 96-Well Plates This kind of cross-species comparison is exactly the data regulatory agencies want when evaluating whether animal findings translate to human risk.
The Regulatory Landscape
The FDA Modernization Act 2.0, signed into law in the United States in late 2022, removed the longstanding requirement that drugs must be tested on animals before entering human clinical trials. The law explicitly allows alternatives to animal testing for drug and biological product applications.21PubMed Central. Alternatives to animal testing to assess MASH drugs and hepatotoxicity This legislative shift has given urgency to the development and validation of platforms like liver organoids, liver-on-chip systems, bioprinted tissues, and precision-cut liver slices. The law does not mandate that these alternatives replace animals overnight, but it opens the door for pharmaceutical companies to submit organoid-based data as part of their safety packages.
Standardization remains a bottleneck, though. Different labs use different cell sources, culture protocols, and readout methods, which makes it hard to compare results across studies. Guidelines have been proposed that address cell source validation, criteria for organoid size and cellular composition, gene expression benchmarks, and standardized functional assays.22PubMed Central. Guidelines for Manufacturing and Application of Organoids: Liver Until the field converges on shared quality standards, regulators will remain cautious about accepting organoid data as a standalone substitute for animal studies.
Transplantation and Regenerative Medicine
The most ambitious application of liver organoids is transplanting them into patients with liver failure. Whole-organ transplants remain the gold standard for end-stage liver disease, but donor organs are scarce and the surgery is major. If functional liver tissue could be grown from a patient’s own cells and delivered to the body, it could either bridge the gap to transplant or, in milder cases, restore enough function to avoid transplant altogether.
Animal studies are encouraging. Encapsulated hepatocyte organoids transplanted into mice with acute liver failure caused by a lethal toxin dose dramatically improved survival: in one experiment, 94% of control mice died by day four, while organoid-treated animals survived at significantly higher rates. The same organoids also rescued mice from acetaminophen-induced liver failure, a more clinically relevant scenario.23Cell Stem Cell. Large-scale generation of quality-assured human hepatocyte organoids for liver failure therapy In chronic disease models, iPSC-derived liver organoids transplanted onto the surface of fibrotic mouse livers reduced scarring through immunomodulatory effects, particularly by promoting a type of macrophage associated with tissue repair.24PubMed. Human iPSC-liver organoid transplantation reduces fibrosis through immunomodulation
Vascularization is one of the critical hurdles. Transplanted tissue dies without a blood supply, and organoids in a dish do not naturally form blood vessels that connect to the host. One approach uses genetic engineering to activate vascular growth factor pathways within organoids, producing an interconnected network of vessels that remains stable over time. When similar constructs were transplanted into immunodeficient mice with liver damage, extensive vascularization and blood perfusion were observed, and the transplanted hepatocytes continued to mature in the host environment.25PubMed Central. Organoid Transplant Approaches for the Liver 26Cell. Generating Functional Human Liver Organoids by Genetic Engineering of Gene Regulatory Networks
Gene editing adds another dimension. Prime editing, a newer and more precise form of CRISPR-based editing, has been used to correct disease-causing mutations in patient-derived liver organoids with no detectable off-target effects at the genome-wide level. For genetic liver diseases like Wilson disease, the vision is to take a patient’s cells, grow organoids, correct the mutation, and transplant the repaired tissue back, a curative strategy that avoids the immune-rejection problems of donor organs.27Cell Proliferation / Wiley Online Library. Liver Organoids: From Disease Modelling to Regenerative Medicine
Biobanking Frozen Tissues for Future Use
One practical challenge that does not get enough attention is logistics. Liver biopsies and surgical explants arrive in the lab on the hospital’s schedule, not the researcher’s. Cryopreservation-enabled workflows let teams freeze tissue samples and generate organoids later, decoupling tissue acquisition from organoid culture. Proof-of-concept studies have shown that organoids derived from cryopreserved human liver tissues retain viability and disease-relevant characteristics, though performance still varies depending on the source material, the specific culture line, and protocol details.28PubMed Central. Biobanked Liver Organoids: A Roadmap for Precision Hepatology For cancer biobanks especially, this flexibility is valuable: a tumor sample frozen years ago can be thawed, expanded into organoids, and tested against drugs that did not even exist when the biopsy was taken.
Connecting the Liver to Other Organs
The liver does not operate in isolation. It receives nutrient-rich blood from the gut via the portal vein, processes metabolites produced by gut bacteria, and sends bile back to the intestine. Modeling this gut-liver axis in vitro requires linking intestinal and liver organoids together, typically through shared media or microfluidic channels. These integrated systems let researchers study questions that neither organ model can answer alone, such as how a leaky gut barrier drives liver inflammation or how certain gut microbe metabolites contribute to fatty liver disease.29PubMed Central. In vitro models of the gut-liver axis: what we’ve learned and what remains to be built The technology is still in its early stages, with researchers working on the technical challenges of maintaining two different tissue types under conditions that keep both healthy, but the direction is clear: single-organ models are giving way to interconnected systems that better represent the body’s actual physiology.
Beyond the gut, groups are exploring liver-kidney, liver-heart, and liver-immune system connections on multi-organ chips. Drug toxicity often involves cascading effects between organs. A compound that is safe for the liver might be converted by liver enzymes into a metabolite that damages the kidney. Only a connected system can capture that sequence. Liver organoids, because of their central role in drug metabolism, are almost always one of the organs included in these multi-tissue platforms.
Where the Gaps Remain
For all the progress, liver organoids still fall short of real liver tissue in several ways. Most organoids remain small, on the order of a few hundred micrometers, and lack the spatial organization of a liver lobule, the repeating unit that creates oxygen and nutrient gradients across the tissue. The metabolic zonation that results from these gradients, where hepatocytes near the blood supply perform different tasks from those farther away, is largely absent in current organoids. Some labs are attempting to recreate zonation using microfluidic gradients, but it remains an unsolved problem.
Immune representation is another gap. While some protocols include macrophages, the full complement of immune cells found in a healthy liver, including natural killer cells, T cells, and dendritic cells, is rarely present. This limits how well organoids can model immune-mediated liver diseases or the immune component of drug reactions. The liver is one of the most immunologically active organs in the body, and capturing that complexity in a dish is a formidable challenge.
Scale-up for therapeutic use also presents real obstacles. Rescuing a mouse from liver failure requires millions of cells. Treating a human would require billions. Producing that many quality-controlled organoid cells in a reproducible, cost-effective way is an industrial engineering problem as much as a biological one. Current protocols work at laboratory scale, and bridging the gap to clinical manufacturing will require automation, real-time quality monitoring, and supply chains for raw materials that meet pharmaceutical-grade standards.